Completed PHASE1 INTERVENTIONAL NCT01947777

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 (DDI)

A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of Rifampin (a CYP3A Inducer) on the Pharmacokinetics of IPI-145 in Healthy Subjects

Sponsor: SecuraBio

Conditions Healthy

Interventions IPI-145 Rifampin

Updated 8 times since 2017 Last updated: Mar 15, 2021 Started: Oct 31, 2013 Primary completion: Nov 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. SecuraBio leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Apr 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Sep 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SecuraBio

Data source: SecuraBio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lenexa, United States